<DOC>
	<DOCNO>NCT02264678</DOCNO>
	<brief_summary>This modular , phase I/ phase 1 b , open-label , multicentre study AZD6738 administer orally combination cytotoxic chemotherapy regimens and/or novel anti-cancer agent , patient advance malignancy . The study design allow investigation optimal combination dose AZD6738 anti-cancer treatment , intensive safety monitoring ensure safety patient . The initial combination investigate AZD6738 carboplatin . The second combination investigate AZD6738 Olaparib . The third combination investigate AZD6738 MEDI4736 .</brief_summary>
	<brief_title>Ascending Doses AZD6738 Combination With Chemotherapy and/or Novel Anti Cancer Agents</brief_title>
	<detailed_description>This modular , phase I , 2 part , open-label , multicentre study AZD6738 , administer orally , combination cytotoxic chemotherapy regimens and/or novel anti-cancer agent , patient advanced/metastatic solid malignancy . The study design allow escalation dose AZD6738 combination standard dose schedule either cytotoxic chemotherapy and/or novel anti-cancer agent , intensive safety monitoring ensure safety patient . There two part combination module study ; part A , dose escalation optional part B , cohort expansion particular patient group . The initial combination module Carboplatin ( module 1 ) . The second combination Olaparib ( module 2 ) . The third combination MEDI4736 ( module 3 ) . The option start combination module decision Safety Review Committee ( SRC ) , base emerge preclinical data , safety tolerability information initial combination . Combinations AZD6738 novel anti-cancer agent may also explore . Once minimally biologically active dose AZD6738 , combination module , identify part A module , SRC may decide commence part B deem necessary . This may include cohort expansion specific patient group explore preliminary anti-tumour activity effect food particular drug combination drug pharmacokinetics .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Principal Inclusion criterion : Aged least 18 The presence solid malignant tumour consider appropriate standard treatment Module 1 2 Part B study expansion , Module 3 : patient must tumour least 1 cm size measure use CT MRI scan Module 1 Part B Study expansion : second line lung adenocarcinoma ATM deficient tumour . Module 2 Part B Study expansion : advanced gastric adenocarcinoma ( include GEJ ) patient ATM deficient ATM proficient tumour : previous treatment PARP inhibitor . Module 3 : advanced recurrent metastatic nonsmall cell lung cancer , head neck squamous cell carcinoma Principal exclusion criterion A diagnosis ataxia telangiectasia Prior exposure ATR inhibitor Bad reaction AZD6738 Module 1 : Contraindicated treatment carboplatin Module 2 : Contraindicated treatment olaparib Module 3 : Contraindicated treatment MEDI4736</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ATM deficient</keyword>
</DOC>